CN Patent

CN120051278A — Pim激酶抑制剂与kras抑制剂的组合

Assigned to Shanghai Xinwan Pharmaceutical Co ltd · Expires 2025-05-27 · 1y expired

What this patent protects

本公开涉及PIM激酶抑制剂和KRAS抑制剂的组合，用于在有需要的受试者中治疗癌症。还提供了包含其的组合物或药盒。本公开还涉及PIM激酶抑制剂，用于在有需要的人类受试者中治疗具有KRAS突变的癌症。

USPTO Abstract

本公开涉及PIM激酶抑制剂和KRAS抑制剂的组合，用于在有需要的受试者中治疗癌症。还提供了包含其的组合物或药盒。本公开还涉及PIM激酶抑制剂，用于在有需要的人类受试者中治疗具有KRAS突变的癌症。

Drugs covered by this patent

Lumakras (SOTORASIB) · Amgen

Patent Metadata

Patent number: CN120051278A
Jurisdiction: CN
Classification: —
Expires: 2025-05-27
Drug substance claim: No
Drug product claim: No
Assignee: Shanghai Xinwan Pharmaceutical Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.